AcouSort

Revolutionizing sample processing of blood and cell culture components

[AcouSort @AcouSort]

We are thrilled to announce the launch of AcouSort's new web page! 🌟
Visit https://t.co/uPCLINfT0x to learn more about our groundbreaking acoustofluidic technology and the solutions we offer for diagnostic applications and cell therapy manufacturing.

[AcouSort @AcouSort]

Discover AcouSort at CYTO 2024!

AcouSort will be at CYTO 2024 in Edinburgh next week to present our innovative sample preparation solutions. If your there, visit us in Booth 58

[AcouSort @AcouSort]

Read the latest news, we will be presenting and exhibiting at CYTO conference: https://t.co/HaeLIbhJi7

[AcouSort @AcouSort]

Exciting news! AcouSort and Gensensor enter collaboration aiming at improving bioreactor culturing. Read more here: https://t.co/rKFnDcfmsP

[AcouSort @AcouSort]

New Publication out!
Interested in lerning more about how acoustofluidics can be used to automate isolation of mononuclear cells from whole blood samples. Have a look at this new publication: https://t.co/0lPwKhlbmw

[AcouSort @AcouSort]

Ever considered automated alternatives for sample preparation and cell wash? perhaps the AcouWash is what you need!
Learn more at https://t.co/uPCLINflaZ

#AcouWash #AcouSort #CellWash #Noneedtocentrifuge #ResearchInnovation #LabAutomation

[AcouSort @AcouSort]

We are currently enjoying ourselves at the 1st Brazilian nanoscale workshop in Rio de Janeiro, presenting AcouTrap and learning the latest about the role of Extracellular vesicles (EVs) in homeostasis and disease together with a team of engaged and renowned researchers.

[AcouSort @AcouSort]

Annual Report 2023
2023 held several important milestones for AcouSort both within the Diagnostic and Cell Therapy business. To learn more, dive into 2023 Annual report: https://t.co/GsFtgKwU3P

[AcouSort @AcouSort]

Q4 showed progress in cell therapy space with the delivery of a test system and an extension of the collaboration into a third project phase in 2024 strengthening our offering for cell therapy sample processing.

Read the Q4 report: https://t.co/DnX2LVg9FG

[AcouSort @AcouSort]

Watch our CEO Torsten Freltoft present AcouSorts activities addressing current challenges in Cell therapy manufacturing: https://t.co/TF2VtTN7Ww

[AcouSort @AcouSort]

Significant technical progress in the AcouSome project – two novel patent applications filed
https://t.co/NDY57VlZhX

[AcouSort @AcouSort]

AcouSort extends collaboration with leading #celltherapy company into a third project phase, taking another step towards the ultimate goal of establishing profitable sales of disposable #OEM components

#picksandshovels #revolutionizingsampleprocessing
https://t.co/qEN2CZs4kF

[AcouSort @AcouSort]

We're having a great time at the @Phacilitate #AdvancedTherapies week!

#revolutionizingsampleprocessing #automation #celltherapy #innovation

[AcouSort @AcouSort]

We're attending the Advanced Therapies Week to extend our #celltherapy network - read more here: https://t.co/rdACpWhI7X.

[AcouSort @AcouSort]

Join us at @Phacilitate #AdvancedTherapies next week!

#celltherapy #CGT #automation #cellprocessing

[AcouSort @AcouSort]

https://t.co/fv69MnygjU

[AcouSort @AcouSort]

Join us at @Phacilitate #AdvancedTherapies next week!

#celltherapy #CGT #automation #cellprocessing

[AcouSort @AcouSort]

AcouSort has changed its IR distribution service to Modular Finance - follow this link to subscribe to press releases: https://t.co/5UcYFWZo3W
#innovation #picksandshovels #celltherapy #diagnostics

[AcouSort @AcouSort]

Don't miss CEO Torsten Freltoft's presentation at Invest Live, starting soon!
The presentation is live streamed here: https://t.co/QebLNtduFQ

[AcouSort @AcouSort]

FDA approval paves the way for AcouSort’s first OEM commercialization within critical care diagnostics - one of the most significant milestones in the history of the company

Read the press release: https://t.co/ajItDE6Xbs

#diagnostics #picksandshovels #innovation #automation

[AcouSort @AcouSort]

AcouSort’s rights issue fully subscribed, resulting in approximately SEK 24.8 million before transaction costs.
https://t.co/YWseU82jLz